Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775952 | 0.84 | NPC1 (0.49) | PKMLMNAKDM4ENPC1ALDH1A1 | |
| SCHEMBL5776483 | 0.79 | CDK1 (0.49) | PKMLMNAKDM4ENPC1ALDH1A1 | |
| SCHEMBL5777062 | 0.79 | NPC1 (0.44) | GPR119PKMLMNAKDM4ENPC1 | |
| SCHEMBL5779459 | 0.76 | NPC1 (0.46) | GPR119PKMLMNAKDM4ENPC1 | |
| SCHEMBL5778725 | 0.76 | KDM4E (0.48) | PKMLMNAKDM4ENPC1ALDH1A1 | |
| SCHEMBL5777821 | 0.76 | NPC1 (0.42) | PKMLMNAKDM4ENPC1ALDH1A1 | |
| SCHEMBL1010203 | 0.73 | MYC (0.62) | PKMLMNAKDM4ENPC1ALDH1A1 | |
| SCHEMBL2431912 | 0.73 | PKM (0.59) | GPR119PKMLMNAKDM4ENPC1 | |
| SCHEMBL5774833 | 0.73 | GPR119 (0.36) | GPR119PKMLMNAKDM4ENPC1 | |
| SCHEMBL5778053 | 0.72 | NAMPT (0.47) | GPR119PKMKDM4ENPC1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | GPR119 2675/4885PKM 3411/4885LMNA 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.